Table 3;
Outcome Summary
| Patient # | sex | age at study DLI | Disease | Overall Disease Risk Index | Status at Transplant | Conditioning regimen | MUD/MRD | Acute GvHD before study DLI, grade and site (Day of transplant) | Chimerism at the time of study DLI, CD3+; CD15+ | Chimerism after study DLI CD3+; CD15+ (Days following DLI) | Days between transplant and study DLI | Reason(s) the study DLI was delayed | Study DLI CD3+/kg (106) | Residual CD45RA+ as % of CD3+ | Residual CD3+ CD45RA+ T cells/kg (106) | Immunosuppression at the time of study DLI | Absolute lymphocyte count at study DLI (x10^6) | Acute GvHD after study DLI, grade and site (days post DLI) | Chronic GvHD after study DLI, severity and site | Viral infections after study DLI | Disease Recurrence, days after study DLI | Unmanipulated DLI (Days post study DLI) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | M | 68 | AML | High | CR | Flu/Mel/Cam | MUD | 3; skin (30) | >98%; >98% | N/A; N/A | 119 | Logistics and GvHD | 0.1 | 26.9 | 0.03 | Pred 10mg qd + MMF 1000mg bid | 1000 | No | N/A | None | 89 | No |
| 2 | F | 54 | MM | Inter | VGPR | Flu/Mel/Cam | MRD | None | 80%; >98% | 76%; >98% (120) | 76 | 0.1 | 12.4 | 0.01 | MMF 1000mg bid | 500 | No | N/A | None | No | Yes (69) | |
| 3 | F | 50 | MM | High | PR | Flu/Mel/Cam | MRD | None | 61%; >98% | 80%; >98% (112) | 105 | Logistics (patient consideration) | 0.1 | 29.6 | 0.03 | MMF 500mg bid | 1100 | No | N/A | CMV viremia | 266 | Yes (119) |
| 4 | M | 30 | HL | High | PR | Flu/Mel/Cam | MRD | None | 76%; >98% | N/A; N/A | 92 | 1 | 8.6 | 0.09 | None | 900 | None | N/A | HHV6 | 72 | No | |
| 5 | M | 65 | NHL | Low | PD | Flu/Mel/Cam | MUD | 3; GI (48) | >98%; >98% | >98%; >98% (95) | 90 | 1 | 0.3 | 0.003 | Pred 10mg qd + MMF 720mg bid | 200 | No | N/A | None | No | No | |
| 6 | M | 55 | NHL | Inter | PR | Flu/Mel/Cam | MRD | 1; skin (47) | >98%; >98% | >98%; >98% (114) | 92 | 1 | 1.2 | 0.01 | MMF 1000mg bid | 200 | No | N/A | None | No | No | |
| 7 | M | 65 | CLL/SLL | Low | CR | Flu/Mel/Cam | MUD | None | 92%; 95% | 94%; >98% (118) | 144 | Technical/logistic | 5 | 20.5 | 1.0 | MMF 500mg bid | 300 | 2, skin + GI (13) | N/A | None | No | No |
| 8 | M | 65 | NHL | Inter | PD | Flu/Mel/Cam | MRD | None | 65%; >98% | 92%; >98% (91) | 97 | Technical/logistic | 5 | 0.5 | 0.02 | MMF 1000mg bid | 100 | No | N/A | None | No | No |
| 9 | F | 41 | NHL | Inter | PD | Flu/Mel/Cam | MUD | 2; skin (68) | >98%; >98% | >98%; >98% (95) | 140 | Pre-DLI GvHD | 5 | 2.2 | 0.1 | None | 600 | No | Mod, lung | None | No | No |
| 10 | M | 61 | AML | Inter | PD | Flu/Mel/Cam | MRD | 2; skin (96) | 98%; >98% | N/A; N/A | 229 | CMV viremia and GvHD | 10 | 2.4 | 0.2 | Pred 20mg qd | 300 | No | N/A | None | No | No |
| 11 | M | 67 | MDS/MPN | Inter | SD | Flu/Mel/Cam | MRD | None | 34%; >98% | 85%; 98% (94) | 113 | Technical/logistic | 10 | 5.0 | 0.5 | MMF 1000mg bid | 200 | No | N/A | None | No | No |
| 12 | F | 44 | AML | Inter | CR | Flu/Mel/Cam | MUD | None | 89%; 88% | 98%; 98% (240) | 78 | 10 | 4.7 | 0.5 | MMF 360mg bid | 840 | No | N/A | None | 720 | Yes (779) | |
| 13 | M | 52 | AML | High | CR | Bu/Cy/ATG | MUD | 2; GI (83) | 94%; >98% | >98%; >98% (87) | 112 | Pre-DLI GvHD | 10 | 0.6 | 0.07 | Pred 10mg qd + Tac 1.5mg qd | 1590 | No | N/A | None | No | No |
| 14 | M | 53 | AML | High | CR | Bu/Cy/ATG | MUD | None | >98%; >98% | >98%; >98% (110) | 119 | Logistics (patient consideration) | 10 | 0.05 | 0.005 | Tac 0.5mg qd | 500 | No | N/A | None | 81 | Yes (109) |
| 15 | M | 47 | MF | Inter | SD | Bu/Cy/ATG | MRD | None | 91%; 98% | 92%; 98% (124) | 280 | bowel obstruction, abscess and complications | 10 | 7.5 | 0.75 | Pred 10mg qd | 2100 | No | N/A | None | 818 | Yes (905) |
| 16 | M | 56 | AML | Inter | CR | Bu/Cy/ATG | MUD | None | 60%; >98% | 88%; >98% (39) | 252 | CMV after transplant; logistics | 10 | 6.5 | 0.65 | None | 1500 | No | N/A | CMV viremia | 44 | Yes (97) |
AML; acute myeloid leukemia, MM; multiple myeloma, HL; Hodgkin lymphoma, NHL; non-hodgkin lymphoma, CLL/SLL; chronic lymphocytic leukemia/small lymphocytic leukemia, MDS/MPN; myelodysplastic syndrome/myeloproliferative disorder, MF; myelofibrosis, CR; complete remission, VGPR; very good partial remission, PR; partial remission, PD; progressive disease, Flu/Mel/Cam; fludarabine/melphalan/campath, Bu/Cy/ATG; busulfan/cyclophosphamide/anti-thymocyte globulin, MUD; matched unrelated donor, MRD, Matched related donor, N/A; not available, Pred; prednisone, MMF; mycophenolate mofetil, Tac; tacrolimus, CMV; cytomegalovirus viremia, HHV6; human herpesvirus 6 viremia